EGFR and non-small cell lung carcinoma: This pooled dataset is in agreement with several large, prospective phase III studies that examined EGFR TKIs as first-line therapy, and strengthens the recommendation that EGFR mutation-positive NSCLC should be treated with erlotinib or gefitinib in the first line.